One systematic review found no clinically important differences between groups receiving cholinesterase inhibitors and those receiving a placebo in the development of behavioral and neuropsychiatric symptoms of Alzheimer’s disease [11]. This evidence concerns the gene BCHE and Alzheimer disease.